United States - English - NLM (National Library of Medicine)

emergent devices inc. - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone hydrochloride 2 mg in 0.1 ml - narcan nasal spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. narcan nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. narcan nasal spray is not a substitute for emergency medical care. limitations of use: restrict prescription of narcan nasal spray 2 mg to opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. narcan nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients. risk summary the limited available data on naloxone use in pregnant women are not sufficient to inform a drug-associated risk. however, there are clinical considerations [see clinical considerations] . in animal reproduction studies, no embryotoxic or teratogenic ef

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

dfl industria e comercio s.a. - articaine (articaine hydrochloride), epinephrine (epinephrine hydrotartrate) - solution for injection - 40mg/ml+ 10mcg/ml

United States - English - NLM (National Library of Medicine)

a-s medication solutions - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - narcan nasal spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. narcan nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. narcan nasal spray is not a substitute for emergency medical care. limitations of use: restrict prescription of narcan nasal spray 2 mg to opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. narcan nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients. risk summary the limited available data on naloxone use in pregnant women are not sufficient to inform a drug-associated risk. however, there are clinical considerations [see clinical considerations] . in animal reproduction studies, no embryotoxic or teratogenic ef

Ireland - English - HPRA (Health Products Regulatory Authority)

emergent operations ireland limited - naloxone hydrochloride dihydrate - nasal spray, solution in single-dose container - 1.8 milligram(s) - antidotes; naloxone

Ireland - English - HPRA (Health Products Regulatory Authority)

emergent operations ireland limited - naloxone hydrochloride dihydrate - nasal spray, solution in single-dose container - 3.6 milligram(s) - antidotes; naloxone

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - naloxone hydrochloride dihydrate 0.4 mg/ml - solution for injection - 0.4 mg/ml - active: naloxone hydrochloride dihydrate 0.4 mg/ml excipient: hydrochloric acid sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - naloxone hydrochloride dihydrate 0.02 mg/ml - solution for injection - 0.02 mg/ml - active: naloxone hydrochloride dihydrate 0.02 mg/ml excipient: hydrochloric acid sodium chloride water for injection

United States - English - NLM (National Library of Medicine)

proficient rx lp - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - narcan nasal spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. narcan nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. narcan nasal spray is not a substitute for emergency medical care. limitations of use: restrict prescription of narcan nasal spray 2 mg to opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. narcan nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients. risk summary the limited available data on naloxone use in pregnant women are not sufficient to inform a drug-associated risk. however, there are clinical considerations [see error! hyperlink reference not valid. ] . in animal reproduction studies, no embryotoxic o

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

dfl industria e comercio s.a. - articaine (articaine hydrochloride), epinephrine (epinephrine hydrotartrate) - solution for injection - 40mg/ml+ 10mcg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

bristol-myers squibb pharma - naloxone hydrochloride - solution for injection - 400 microgram/ml